Internal Medicine, Medical Oncology · Davenport, FL
NPI
1497929319
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
40215 Highway 27
Davenport, FL, 33837
Phone (863) 421-9705
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.3M
429,334 services
Medicare patients, 2024
1,213
Average age 76
Drug cost, 2024
$10.3M
2,677 prescriptions
Company payments, 2025
$5,542
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wasif Riaz was code J1756 (injection, iron sucrose, 1 mg), 30,400 times for 45 patients. In total Wasif Riaz billed 429,334 services in 172 codes, and Medicare paid $7.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 30,400 | 45 | $0.17 | $5,177 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 24,660 | 14 | $39.27 | $968K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 24,480 | 32 | $0.26 | $6,485 |
| J0897 Injection, denosumab, 1 mg | Office | 18,000 | 113 | $20.46 | $368K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 16,200 | 18 | $44.63 | $723K |
| J0185 Injection, aprepitant, 1 mg | Office | 13,000 | 26 | $1.33 | $17K |
| J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 12,660 | 13 | $0.78 | $9,830 |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 12,540 | 12 | $0.22 | $2,724 |
| J9267 Injection, paclitaxel, 1 mg | Office | 12,389 | 12 | $0.08 | $994 |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 7,200 | 19 | $2.26 | $16K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 7,040 | 17 | $35.37 | $249K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 6,130 | 38 | $6.36 | $39K |
| J9173 Injection, durvalumab, 10 mg | Office | 6,026 | 12 | $63.51 | $383K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,264 | 87 | $0.09 | $473 |
| 85025 Blood Count | Office | 3,392 | 836 | $7.59 | $26K |
By year: 2022 $6.8M for 472,192 services; 2023 $6.8M for 474,546 services; 2024 $7.3M for 429,334 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,392 | 836 | $7.59 | $26K |
| 36415 Venipuncture Blood Collection | 3,054 | 818 | $8.65 | $26K |
| 81003 Clinical Chemistry | 77 | 37 | $2.20 | $169 |
Medicare prescription drug claims, 2024
In 2024, the drug Wasif Riaz prescribed most often to Medicare patients was Revlimid (Lenalidomide), with 220 prescriptions and refills. In total Wasif Riaz wrote 2,677 Medicare prescriptions that cost $10.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | 220 | 220 | 30 | $3.8M |
| Prochlorperazine Maleate Generic | 156 | 156 | 110 | $4,398 |
| Ondansetron Odt Ondansetron | 144 | 144 | 122 | $6,539 |
| Oxycodone Hcl Generic | 125 | 125 | 48 | $3,175 |
| Anastrozole Generic | 123 | 356 | 61 | $1,945 |
| Acyclovir Generic | 95 | 227 | 37 | $2,120 |
| Letrozole Generic | 94 | 282 | 42 | $2,288 |
| Gabapentin Generic | 77 | 111 | 27 | $1,554 |
| Eliquis Apixaban | 70 | 111 | 28 | $61K |
| Tramadol Hcl Generic | 65 | 65 | 38 | $709 |
| Dexamethasone Generic | 55 | 84 | 26 | $1,375 |
| Xtandi Enzalutamide | 54 | 54 | Under 11 | $750K |
| Prednisone Generic | 52 | 86 | 25 | $521 |
| Levofloxacin Generic | 48 | 60 | 39 | $392 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 45 | 45 | Under 11 | $1,517 |
Brand drugs: 761 claims; generic drugs: 1,916 claims; opioid claims: 314.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wasif Riaz $5,542 ($5,542 in general payments such as food, travel and fees) from 50 companies. The largest payer was Janssen Biotech, Inc. with $626.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 29 | $626 |
| AstraZeneca Pharmaceuticals LP AZN | 15 | $379 |
| Novartis Pharmaceuticals Corporation NVS | 20 | $376 |
| Pfizer Inc. PFE | 25 | $358 |
| Astellas Pharma US Inc 4503.T | 14 | $358 |
| Celgene Corporation BMY | 8 | $249 |
| Daiichi Sankyo Inc. 4568.T | 9 | $225 |
| GlaxoSmithKline, LLC. GSK | 8 | $194 |
| Abbvie Inc. ABBV | 9 | $187 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $178 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.